AI drug discovery company

Superluminal Medicines

Data as of Oct 17, 2026.

Company facts

Founded

2022

ReportedSource for founded (opens in new tab)
Headquarters

United States (Boston, MA)

ConfirmedSource for headquarters (opens in new tab)

Latest funding round

Round: Series B
Date: Sep 2026
Amount: $60M
Lead investor: BVF Partners

ConfirmedSource for the latest round (opens in new tab)

Drug discovery partners

1 pharma, 1 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.

Eli Lilly Pharma

Small-molecule collaboration (cardiometabolic, obesity), Aug 14, 2025

$1.3B total potential (upfront not disclosed)

ReportedSource for Eli Lilly (opens in new tab)
Axcelead DDP CRO

Intent to collaborate on drug discovery, Jun 2025

Terms not disclosed

ConfirmedSource for Axcelead DDP (opens in new tab)

Recent news

Sep 4, 2026

$60M Series B, ML-driven GPCR discovery; lead obesity program entering Phase 1

ReportedSource (opens in new tab)
Aug 14, 2025

Eli Lilly collaboration on cardiometabolic and obesity small molecules, reported at up to $1.3B

ReportedSource (opens in new tab)
Jun 2025

Intent to collaborate on drug discovery with Axcelead DDP

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.